Article
Molecular characterization of respiratory syncytial viruses infecting children reported to have received palivizumab immunoprophylaxis.
Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology - 1 Apr 2015
Oliveira Danielle B L, Iwane Marika K, Prill Mila M, Weinberg Geoffrey A, Williams John V, Griffin Marie R, Szilagyi Peter G, Edwards Kathryn M, Staat Mary A, Hall Caroline B, Durigon Edison L, Erdman Dean D
Abstract excerpt
BACKGROUND: Respiratory syncytial virus (RSV) is a major cause of respiratory infections in children. Palivizumab (PZ) is the only RSV-specific immunoprophylaxis approved by the U.S. Food and Drug Administration. Mutations leading to amino acid substitutions in the PZ binding site of the RSV F protein have been associated with breakthrough RSV infections in patients receiving PZ. OBJECTIVE: To detect PZ...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.